Congestive Heart Failure (CHF) Treatment Devices Market - By Product (Defibrillator [ICD, External], Pacemaker, Cardiac Resynchronization Therapy Device, Ventricular Assist Device [LVAD, RVAD]), End-use (Hospital, Cardiac Clinic) – Global Forecast 2024 – 2032

Congestive Heart Failure (CHF) Treatment Devices Market - By Product (Defibrillator [ICD, External], Pacemaker, Cardiac Resynchronization Therapy Device, Ventricular Assist Device [LVAD, RVAD]), End-use (Hospital, Cardiac Clinic) – Global Forecast 2024 – 2032

Congestive Heart Failure Treatment Devices Market Size

Congestive Heart Failure (CHF) Treatment Devices Market size was valued at around USD 23.5 billion in 2023 and is estimated to expand at 6.4% CAGR from 2023 to 2032. This robust market growth can be attributed to various factors, including rising prevalence of heart failure and cardiovascular diseases, favorable reimbursement scenario, and an increasing awareness regarding heart failure treatment, among other contributing factors.
 

The prevalence of heart failures has increased significantly with the aging global population. This demographic shift plays a crucial role in driving the demand for congestive heart failure treatment devices. For instance, according to a report published by the British Heart Foundation, in 2024, heart failure (HF) affects an estimated 64 million people globally, similarly, in 2021, HF accounted for 20.5 million deaths. In addition, the number of those diagnosed with HF is expected to rise 46% by 2030. Therefore, these statistics highlights the increasing demand for CHF treatment devices to effectively address and prevent heart failures and related conditions.
 

Moreover, organizations dedicated to cardiovascular health, such as the American Heart Association (AHA), World Heart Organization (WHO), and various national heart foundations, actively engage in advocacy and awareness initiatives. By fostering informed decision-making among patients, caregivers, and healthcare professionals, this growing awareness contributes to a more proactive and effective approach to managing heart failure, thereby contributing to the market expanison.
 

Congestive heart failure treatment devices refer to a diverse range of medical devices designed to aid in the management and improvement of individuals suffering from heart failure. These treatment devices aim to address various aspects of heart failure, including enhancing cardiac function, managing symptoms, and improving overall quality of life for affected individuals.
 

Congestive Heart Failure Treatment Devices Market Trends

The market is experiencing robust growth, propelled by continuous technological advancements and the introduction of innovative devices. The integration of medical science and cutting-edge technology has resulted in the development of advanced treatment options for individuals suffering from congestive heart failure.
 

• Ongoing technological breakthroughs have led to the development of highly sophisticated implantable devices such as pacemakers, implantable cardioverter-defibrillators (ICDs), and cardiac resynchronization therapy (CRT) devices. For instance, in January 2023, Boston Scientific launched the EMBLEM MRI S-ICD systems in Europe.
   
• Similarly, in September 2022, Abbott received the U.S. Food and Drug Administration (FDA) approval for its Gallant CRT-D and CRT-P devices. These devices incorporate advanced algorithms, remote monitoring capabilities, and enhanced energy efficiency, contributing to better patient outcomes.
   
• Moreover, artificial intelligence (AI) and machine learning algorithms are increasingly being incorporated into CHF treatment devices to analyze complex datasets. These technologies enable predictive analytics, helping healthcare providers identify potential complications and tailor treatment plans based on individual patient profiles.

Congestive Heart Failure Treatment Devices Market Analysis

The congestive heart failure treatment devices market by product is categorized into defibrillators, pacemakers, cardiac resynchronization therapy devices, ventricular assist devices (VADs), and other products. The defibrillators segment accounted for 52.6% market share in 2023 and is anticipated to witness significant growth during the forecast period.­
 

• Defibrillators are critical in preventing sudden cardiac arrest, a life-threatening event that individuals with CHF may be susceptible to. The rapid delivery of an electric shock by defibrillators can restore normal heart rhythm, averting a potentially fatal outcome. Defibrillators are further classified into implantable cardioverter defibrillators and external cardioverter defibrillators.
   
• Implantable cardioverter defibrillators have evolved from single-chamber to dual-chamber to biventricular devices, offering more options and flexibility for CHF patients with different types and degrees of arrythmias. These devices are surgically implanted to continuously monitor heart rhythm. In the event of detected irregularities or dangerous arrhythmias, ICDs deliver precisely timed electric shocks to restore normal cardiac function.
   
• Moreover, defibrillators are extensively utilized in hospital settings, emergency departments, and cardiac care units. Their rapid deployment in these healthcare settings reinforces the segment's dominant market position, especially in acute care scenarios related to CHF complications.

The CHF treatment devices market by end-use is categorized into hospitals, cardiac clinics, ambulatory surgical centers, and other end-users. The hospitals segment accounted for around USD 10.5 billion revenue size in 2023.
 

• According to an article published by the National Library of Medicine, in 2021, Heart failure (HF) is one of the leading causes of hospital admission in the U.S. with over 1 million hospitalizations occurring annually, accounting for almost 6.5 million hospital days every year. Hospitals offer comprehensive cardiac care facilities equipped with state-of-the-art infrastructure, specialized healthcare professionals, and advanced medical technologies. This makes hospitals the primary setting for the diagnosis and management of CHF, including the deployment of treatment devices.
   
• Additionally, hospitals play a pivotal role in the implantation of various cardiac devices used in CHF management. This includes implantable cardioverter-defibrillators (ICDs), pacemakers, left ventricular assist devices (LVADs), and cardiac resynchronization therapy (CRT) devices. The expertise available in hospitals ensures the proper implantation and ongoing management of these devices. Therefore, the central role of hospitals in providing a comprehensive range of services across diverse specialties will fuel business growth positively.

North America congestive heart failure treatment devices market accounted for USD 10.3 billion revenue in 2023 and is predicted to witness substantial market growth over the analysis timeline.
 

• This notable market share can be attributed to various factors, including the presence of leading industry players, an increasing demand for cardiovascular devices, a rising incidence of cardiovascular conditions, and the growing number of hospital admissions throughout the country, among other key drivers.
   
• For instance, according to the Centers for Disease Prevention and Control (CDC) statistics, in 2020, cardiac disease was the leading cause of mortality in the U.S., accounting for around 697,000 deaths.
   
• Further, in the U.S., cardiac diseases have a heavy disease burden, costing approximately USD 229 billion every year from 2017 to 2018. Thus, the significant disease burden, high prevalence, & mortality rate are set to drive cardiac rhythm management devices market growth in the region.
   
• Furthermore, patients in the region are generally well-informed about healthcare options and often seek advanced and minimally invasive treatments. The growing demand from patients for effective and sophisticated solutions, such as congestive heart failure treatment devices, influences healthcare providers to offer these procedures.
   

Congestive Heart Failure Treatment Devices Market Share

The congestive heart failure treatment devices industry is competitive in nature, with several large multinationals, small and mid-sized companies competing in the industry. The development and launch of novel advanced products based on different technologies are among a key market strategy. Some of the leading industry players including Abbott Laboratories, Biotronik SE & Co. KG, Boston Scientific Corporation, Medtronic plc, among others have a notable presence in the market.
 

Congestive Heart Failure Treatment Devices Market Companies

Some of the eminent market participants operating in the congestive heart failure treatment devices industry include

• Abbott Laboratories
• Biotronik SE & Co. KG
• Boston Scientific Corporation
• Koninkilijke Philips N.V.
• Lepu Medical Technology Co. Ltd.
• LivaNova PLC
• MEDICO S.p.A.
• Medtronic plc
• MicroPort Scientific Corporation
• OSCOR Inc.
• Schiller AG
• Shree Pacetronix Ltd.
• St. Jude Medical, Inc.
• Stryker Corporation
• Terumo Corporation
   

Congestive Heart Failure Treatment Devices Industry News

• In May 2023, Medtronic plc announced U.S. Food and Drug Administration (FDA) approval of its Micra AV2 and Micra VR2, the next generation of its industry-leading miniaturized, leadless pacemaker. This product approval may help the company to enhance their cardiac rhythm management devices product portfolio and generate increased business revenue.
   
• In January 2019, Microport CRM, a business unit of Microport Scientific Corporation, announced the European launch of their next-generation pacemaker products. This initiative has helped the company increase their market share and revenue generation in the European market.
   

Congestive heart failure treatment devices market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments

Click here to Buy Section of this Report

Market, By Product

• Defibrillators
  • Implantable cardioverter defibrillators (ICDs)
    • Transvenous ICD
      • Single-chamber ICDs
      • Dual-chamber ICDs
    • Subcutaneous ICD
• External cardioverter defibrillator
  • Manual external defibrillator
  • Automated external defibrillator
    • Semi-automated external defibrillator
    • Fully automated external defibrillator
  • Wearable external cardioverter defibrillator 
• Pacemakers
  • Implantable pacemakers
  • External pacemakers
• Cardiac resynchronization therapy devices
  • Cardiac resynchronization therapy-defibrillators (CRT-D)
    • MRI compatible CRT-D devices
    • Conventional CRT-D devices
  • Cardiac resynchronization therapy-pacemakers (CRT-P)
    • MRI Compatible CRT-P devices
    • Conventional CRT-P devices
• Ventricular assist devices (VADs)
  • Left ventricular assist devices (LVADs)
  • Right ventricular assist devices (RVADs)
  • Biventricular assist devices (BIVADs)
  • Percutaneous ventricular assist devices (PVADs)
  • Total artificial heart
• Other products

Market, By End-use

• Hospitals
• Cardiac clinics
• Ambulatory surgical centers
• Other end-users

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa